Jazz Pharmaceuticals Plc

As of August 5, 2025, Jazz Pharmaceuticals Plc is considered overvalued with a P/E ratio of 14 compared to the peer average of 16.11, a PEG ratio of 0.68 indicating reasonable growth potential, and mixed performance results, including a 1-year stock return of 19.74% versus the S&P 500's 17.14%, but a disappointing 3-year return of -11.05% compared to the S&P 500's 70.41%.

As of May 7, 2025, Jazz Pharmaceuticals Plc is considered an attractive investment due to its undervalued status with a P/E ratio of 14, a PEG ratio of 0.68, and an EV to EBITDA ratio of 7.69, despite a year-to-date return of -13.31% compared to the S&P 500's 2.44%.

As of May 29, 2025, the market trend is mildly bearish, indicated by bearish momentum from the weekly MACD and KST, while monthly indicators show a mildly bullish outlook, with moving averages and Bollinger Bands also reflecting bearish trends.

As of March 2022, the management team of Jazz Pharmaceuticals Plc includes Chairman and CEO Bruce Cozadd, Directors Jennifer Cook and Mark Smith, and Independent Directors Paul Berns, Patrick Enright, and Peter Gray. They are responsible for the company's strategic direction and operations.

Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing products for unmet medical needs. As of March 2025, it reported net sales of $898 million and a net profit of -$93 million, with a market cap of $6.48 billion.

As of Jun 18, Jazz Pharmaceuticals Plc has a market capitalization of 6,477.70 million, with net sales of 4,064.81 million and net profit of 482.21 million over the latest four quarters. Shareholder's funds are 4,093.76 million, and total assets amount to 12,012.26 million.